Remalda Sues Laidlaw

Remalda Sues Laidlaw

I recently read that the New York-based Relmada Therapeutics, Inc. develops innovative therapies for the treatment of chronic pain. They have previously filed a complaint against Laidlaw & Company Ltd. The complaint says while acting as an investment banker on behalf of Remalda, Laidlaw was given confidential company information which they then unethically disclosed. The firm is in the process of seeking financial reimbursement for the loss of money it incurred because of this breach. Remalda has also filed a temporary restraining order and injunction against Laidlaw and its principals, Matthew Eitner and James Ahern.

Apparently, Remalda thinks that Laidlaw can do more damage and thus the restraining order. Its stockholders are being kept in the loop concerning all of Remalda’s actions against Laidlaw. The company management has always kept the stockholders informed about everything which is one reason the stockholders in turn have a complete confidence in the management. This bond between company management and stakeholders has created a very peaceful environment that has encouraged the inspiration that has resulted in the creation of innovative new treatments.

And the stockholders have allowed the management and Board of Directors to deal with the suit against Laidlaw to their discretion. As mentioned, Matthew Eitner and James Ahern are the principals of Laidlaw & Company. Eitner was previously employed by Casimir Capital, NDB Capital Markets, and International Strategy & Investment. He joined the Laidlaw team in 2010 and was made its CEO in 2011. Serving in a professional capacity is not his only service to society. He also frequently assists with the operations of several charities. He is assisted at Laidlaw by James Ahern, the other principal of Laidlaw. He also joined the Laidlaw team in 2010 and has since that time successfully overseen and grown the firms market share expansion. Like Eitner, Ahern is also very active in support of several different charities.

0 Comments

Add Your Comment: